12:27:06 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-03-15 Ordinarie utdelning ALK B 0.00 DKK
2024-03-14 Årsstämma 2024
2024-02-08 Bokslutskommuniké 2023
2023-11-15 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-09 Kvartalsrapport 2023-Q1
2023-03-20 Ordinarie utdelning ALK B 0.00 DKK
2023-02-03 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-03-28 Split ALK B 1:20
2022-03-17 Ordinarie utdelning ALK B 0.00 DKK
2022-03-16 Årsstämma 2022
2022-02-08 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-05-05 Kvartalsrapport 2021-Q1
2021-03-19 Ordinarie utdelning ALK B 0.00 DKK
2021-03-18 Årsstämma 2021
2021-02-10 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-05-06 Kvartalsrapport 2020-Q1
2020-03-12 Ordinarie utdelning ALK B 0.00 DKK
2020-03-11 Årsstämma 2020
2020-02-05 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-13 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-03-14 Ordinarie utdelning ALK B 0.00 DKK
2019-03-13 Årsstämma 2019
2019-02-07 Bokslutskommuniké 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-04 Kvartalsrapport 2018-Q1
2018-03-13 Ordinarie utdelning ALK B 0.00 DKK
2018-03-12 Årsstämma 2018
2018-02-06 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-09 Kvartalsrapport 2017-Q1
2017-03-16 Ordinarie utdelning ALK B 5.00 DKK
2017-03-15 Årsstämma 2017
2017-02-07 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-16 Kvartalsrapport 2016-Q2
2016-05-04 Kvartalsrapport 2016-Q1
2016-03-11 Ordinarie utdelning ALK B 5.00 DKK
2016-03-10 Årsstämma 2016
2016-02-09 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-05-05 Kvartalsrapport 2015-Q1
2015-03-13 Ordinarie utdelning ALK B 5.00 DKK
2015-03-12 Årsstämma 2015
2015-02-09 Bokslutskommuniké 2014
2014-11-14 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-03-13 Ordinarie utdelning ALK B 5.00 DKK
2014-03-12 Årsstämma 2014
2014-02-05 Bokslutskommuniké 2013
2013-11-08 Kvartalsrapport 2013-Q3
2013-08-14 Kvartalsrapport 2013-Q2
2013-05-03 Kvartalsrapport 2013-Q1
2013-03-13 Ordinarie utdelning ALK B 5.00 DKK
2013-03-12 Årsstämma 2013
2013-02-05 Bokslutskommuniké 2012
2012-11-12 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-05-10 Kvartalsrapport 2012-Q1
2012-03-28 Ordinarie utdelning ALK B 5.00 DKK
2012-03-27 Årsstämma 2012
2012-02-22 Bokslutskommuniké 2011
2011-11-11 Kvartalsrapport 2011-Q3
2011-08-16 Kvartalsrapport 2011-Q2
2011-05-10 Kvartalsrapport 2011-Q1
2011-04-04 Ordinarie utdelning ALK B 5.00 DKK
2011-04-01 Årsstämma 2011
2010-03-29 Ordinarie utdelning ALK B 5.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
AlK-Abelló är verksamma inom läkemedelsbranschen. Bolaget är en utvecklare av allergi- och immunterapi. Verksamhet innehas på global nivå och produkterna säljs både som vaccin och i tablettform. En stor del av verksamheten fokuserar mot forskning och utveckling inom nämnt arbetsområde, där bolaget aktivt arbetar med diagnostisering och behandling av återkommande allergibesvär. Bolaget grundades 1923 och har sitt huvudkontor i Hørsholm.
2022-11-10 07:30:00

Bemærk venligst, at rapporten udelukkede findes på engelsk.

        
ALK reports Q3 revenue up 11% and updates its full-year outlook (unaudited)

ALK’s revenue grew by 11% in Q3 driven by tablets and Jext®, with growth in all regions. Year-to-date revenue grew 13%, with tablet sales up 19% and profits up 27%. Based on stronger sales in the non-tablet portfolio, ALK is updating its full-year outlook.

Q3 2022 financial highlights

  • Total revenue was up 11% in local currencies at DKK 1,062 million (928). Currencies had a positive effect of 3 percentage points, resulting in reported growth of 14%.
  • Tablet sales increased 13% to DKK 458 million (398) which were slightly lower than expected. In addition, it builds on a very strong Q3 last year where sales were up 41%.
  • Sales of Other products increased by 29%, primarily on strong sales of Jext® in Europe and life sciences products in North America, while combined sales of SCIT and SLIT-drops grew by 1%.
  • Revenue in Europe was up 6%, with North America increasing 16%, and International markets up 24%.
  • Operating profit (EBITDA) for the quarter was DKK 128 million (124), leading to an increase of 27% for the first nine months to DKK 507 million (398) on the double-digit sales growth and improved gross margin, while R&D and sales & marketing expenses grew largely as planned.

Key events and strategic progress

ALK continued to make progress on its strategic priorities and remained resilient in the light of world events. In Q3:

  • The ongoing paediatric Phase III trials in allergic rhinitis (MT-12 and TT-06) progressed as planned and the first patients have been recruited for the Phase I trial (PT-01) with the SLIT-tablet treatment for peanut allergy.

2022 financial outlook

Based on current performance and expectations to sales of the non-tablet portfolio, ALK has updated its full-year outlook:

  • Revenue is now expected to grow 11-13% in local currencies (previously: 10-13%) with higher-than-expected sales of the non-tablet portfolio. Tablet sales growth is now expected to be below 20% (previously: 20% or more), primarily based on a somewhat weaker performance in Europe.
  • EBITDA is still expected to increase to DKK 675-750 million.

Hørsholm, 10 November 2022

ALK-Abelló A/S

Comparative figures for 2021 are shown in brackets. Revenue growth rates are stated in local currencies, unless otherwise indicated

For further information, contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014        

Today, ALK is hosting a conference call for analysts and investors at 1.30 p.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net where the relevant presentation is available shortly before the call begins. Please call in before 1.25 p.m. (CET). Danish participants should call in on tel. +45 7877 4197 and international participants should call in on tel. +44 808 101 1183 or +1 785 424 1603. Please use the Participant Pin Code: 40721#